Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Bioqube Ventures is a global life sciences investment firm founded in 2015, with offices located in Belgium and the United States. The firm is dedicated to transforming scientific discoveries into medicines that address significant unmet medical needs. With a stage-agnostic investment approach, Bioqube Ventures supports companies from their inception through early clinical milestones, ensuring that they have the necessary resources and guidance to succeed in the competitive biotech landscape. Since its inception, Bioqube Ventures has raised multiple funds and has established a reputation for its disciplined investment strategy and commitment to innovation in the life sciences sector.
The firm’s leadership team comprises experienced professionals with deep expertise in biotechnology and healthcare, enabling them to identify and nurture promising startups. Bioqube Ventures has a global presence, focusing primarily on investment opportunities in Europe and North America, which allows them to tap into diverse markets and innovative research environments. Their approach is characterized by a strong emphasis on scientific rationale and execution discipline, making them a preferred partner for early-stage biotech companies.
Bioqube Ventures specializes in investing in companies that are developing first- or best-in-class therapeutics. Their investment strategy encompasses venture creation, early-stage company building, and selective clinical co-investment, which allows them to provide tailored support to their portfolio companies. The firm primarily focuses on the life sciences sector, particularly in biotech and healthcare, where they seek to back innovative companies that are addressing critical medical challenges.
The firm’s stage-agnostic approach means that they are willing to invest at various stages of a company’s development, including Pre Seed, Seed, Seed Plus, Series A, Series B, and Series C. This flexibility enables Bioqube Ventures to engage with startups at different points in their growth trajectory, providing them with the necessary capital and strategic guidance to navigate the complexities of clinical development. By emphasizing a strong biological rationale in their investment decisions, Bioqube Ventures aims to support companies that have the potential to make significant advancements in therapeutic areas.
Bioqube Ventures has built a diverse portfolio of over 20 biotech companies since its founding. Notable investments include **Primmune Therapeutics**, which is currently engaged in clinical studies for melanoma, and **CatalYm**, focused on developing innovative therapies for cancer treatment. Another significant portfolio company is **Bicara Therapeutics**, recognized for its breakthrough therapy designation from the U.S. FDA, highlighting its potential impact in the oncology space.
Additionally, **SynOx Therapeutics** is involved in clinical trials for cancer therapies, while **Spica Therapeutics** is developing macrophage-targeted cancer therapies. These companies exemplify Bioqube Ventures' commitment to supporting cutting-edge research and development in the life sciences sector. The firm’s strategic investments reflect its focus on fostering innovation and addressing unmet medical needs through advanced therapeutic solutions.
To pitch Bioqube Ventures, founders should prepare a detailed presentation that highlights their innovative approach and market potential. While specific submission guidelines are not provided, a well-structured pitch is essential for consideration. It is advisable to reach out through their official website for any specific instructions or contact details.
Recently, Bioqube Ventures has been active in enhancing its leadership team, with the appointment of Tessa Ceyssens as Chief Operating Officer. Additionally, the firm has supported its portfolio company, Primmune Therapeutics, in closing an additional round of Series B financing. These developments reflect Bioqube Ventures' commitment to strengthening its operational capabilities and supporting the growth of its portfolio companies.
Bioqube Ventures invests across multiple stages, including Pre Seed, Seed, Seed Plus, Series A, Series B, and Series C. This stage-agnostic approach allows them to support companies at various points in their development journey.
To pitch Bioqube Ventures, founders should prepare a comprehensive presentation that outlines their business model, scientific rationale, and market potential. While specific submission guidelines are not provided, a well-structured pitch is essential for consideration.
Bioqube Ventures primarily focuses on the life sciences sector, with a particular emphasis on biotech and healthcare. They seek to invest in companies that are developing innovative therapeutics to address significant medical needs.
The specific check sizes are not disclosed in the source material. However, given their stage-agnostic approach, they likely vary depending on the stage of the company and its funding requirements.
Bioqube Ventures has a global investment focus, with particular attention to opportunities in Europe and North America. This geographic diversity allows them to tap into various innovation ecosystems.
Bioqube Ventures provides strategic support to its portfolio companies, including guidance through early clinical milestones and access to their extensive network in the life sciences sector. This support is crucial for startups navigating the complexities of drug development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.